Russian Journal of OncologyRussian Journal of OncologyРоссийский онкологический журнал1028-99842412-9119Eco-Vector4014510.17816/onco40145ArticlesСтатьиResearch ArticleBreast cancer screening: world experience and prospectsСкрининг рака молочной железы: мировой опыт и перспективыKolyadinaIrina V.КолядинаИрина Владимировна

MD, PhD

канд. мед. наук, врач-онколог, хирург, доцент каф. онкологии ГБОУ ДПО РМАПО Минздрава РФ

irinakolyadina@yandex.ruPoddubnayaI. VПоддубнаяИ. ВKomovD. VКомовД. ВRussian Medical Academy of Postgraduate EducationГБОУ ДПО «Российская медицинская академия последипломного образования» Минздрава РоссииN.N. Blokhin Russian Cancer Research CenterФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина»15022015201VOL 20, NO1 (2015)ТОМ 20, №1 (2015)424622072020Copyright ©; 2015, Eco-VectorCopyright ©; 2015, ООО "Эко-Вектор"2015Eco-VectorООО "Эко-Вектор"https://rjonco.com/1028-9984/article/view/40145

Breast cancer screening (breast examination in potentially healthy women for early, preclinical detection of malignancies) was introduced in the 60s last century in the United States, and then in the number of countries in the world. Many years of experience has shown important clinical and prognostic value of mammographic screening programs for increasing the proportion of carcinoma in situ and breast cancer stage I, which led to significant improvement in the long-term survival. The review presents the main stages of the screening programs, differences in the organization of screening in different countries, and also gives the definition of «screening age,» high-risk factors for breast cancer appearing and possible intensification of early detection programs. The existing screening methods have described, their advantages and disadvantages, as well as highlighted possible areas for screening programs.

Скрининг рака молочной железы (исследование молочных желез у потенциально здоровых женщин с целью раннего, доклинического выявления злокачественных опухолей) был введен в 60-х годах прошлого столетия в США, а затем в ряде стран мира. Многолетний опыт показал важное клиническое и прогностическое значение программ маммографического скрининга за счет увеличения доли рака in situ и рака молочной железы I стадии, что привело к существенному улучшению показателей отдаленной выживаемости. В обзоре представлены основные этапы формирования скрининговых программ, различия в организации проведения скрининга в различных странах мира, а также даны определения «скринингового возраста», факторов высокого риска развития рака молочной железы и представлены возможности интенсификации программ ранней диагностики. Дано подробное описание существующих методов скрининга, их преимущества и недостатки, а также выделены возможные направления развития скрининговых программ.

breast cancer screeningmammographyultrasonographyMR breast imagingscreening agerisk factors for breast cancerскрининг рака молочной железымаммографияУЗИМРТ молочных железпонятие «скринингового возраста»факторы риска развития рака молочной железыThomas B.A., Price J.L., Boulter P.S., Gibbs N.M. The first three years of the Guildford Breast Screening Project. Recent Results Cancer Res. 1984; 90: 195-9.Smart C.R., Byrne C., Smith R.A et al. Twenty-year follow-up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project. CA. Cancer J. Clin. 1997; 47(3): 134-49.Tabar L., Yen M.F., Vitak B. et al. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet. 2003; 361: 1405-10.Saika K., Sobue T. Cancer statistics in the world. Gan To Kagaku Ryoho. 2013; 40(13): 2475-80.Rauscher G.H., Murphy A.M., Orsi J.M. et al. Beyond the mammography quality standards act: measuring the quality of breast cancer screening programs. Am. J. Roentgenol. 2014; 202(1): 145-51.Timmers J.M., den Heeten G.J., Adang E.M. et al. Dutch digital breast cancer screening: implications for breast cancer care. Eur. J. Publ. Hlth. 2012; 22(6): 925-9.Corsetti V., Ferrari A., Ghirardi M. et al. Role of ultrasonography in detecting mammographically occult breast carcinoma in women with dense breasts. Radiol. Med. 2006; 111(3): 440-8.Tohno E., Ueno E., Watanabe H. Ultrasound screening of breast cancer. Breast Cancer. 2009; 16(1): 18-22.Berg W.A., Blume J.D., Cormack J.B. et al. ACRIN 6666 Investigators. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. J.A.M.A. 2008; 299(18): 2151-63.Salem D.S., Kamal R.M., Mansour S.M., Salah L.A., Wessam R. Breast imaging in the young: the role of magnetic resonance imaging in breast cancer screening, diagnosisand follow-up. J. Thorac. Dis. 2013; 5(Suppl. 1): S9-S18.Baker J.A., Lo J.Y. Breast tomosynthesis: state-of-the-art and review of the literature. Acad. Radiol. 2011; 18(10): 1298-310.Lalji U., Lobbes M. Contrast-enhanced dual-energy mammography: a promising new imaging tool in breast cancer detection. Womens Hlth (Lond.). 2014; 10(3): 289-98.BlueCross BlueShield Association. Breast-specific gamma imaging (BSGI), molecular breast imaging (MBI), or scintimammography with breast-specific gamma camera. Technol. Eval. Cent. Assess. Program Exec. Summ. 2013; 28(2): 1-4.Jatoi I. Breast cancer screening recommendations. J.A.M.A. 2013; 310(19): 2101-2.Smith R.A., Duffy S.W., Gabe R., Tabar L., Yen A.M., Chen T.H. The randomized trials of breast cancer screening: what have we learned? Radiol. Clin. N. Am. 2004; 42: 793-806.Arleo E.K., Dashevsky B.Z., Reichman M., Babagbemi K., Drotman M., Rosenblatt R. Screening mammography for women in their 40s: a retrospective study of the potential impact of the U.S. Preventive Service Task Force’s 2009 breast cancer screening recommendations. Am. J. Roentgenol. 2013 Dec; 201(6):1401-6.Health Quality Ontario. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis. Ontario Hlth Technol. Assess. Ser. 2007; 7(1): 1-32.Michell M.J. Breast screening review-a radiologist’s perspective. Br. J. Radiol. 2012; 85(1015): 845-7.Langagergaard V., Garne J.P., Vejborg I. et al. Existing data sources for clinical epidemiology: the Danish Quality Database of Mammography Screening. Clin. Epidemiol. 2013; 5: 81-8.Wang B., He M., Wang L. et al. Breast cancer screening among adult women in China, 2010. Prev. Chronic Dis. 2013; 10: 130-6.Nagtegaal D., Allgood P.C., Duffy S.W. et al. Prognosis and pathology of screen-detected carcinomas how different are they? J. Cancer. 2011; 117: 1360-8.Turati F., Negri E., La Vecchia C. Family history and the risk of cancer: genetic factors influencing multiple cancer sites. Expert. Rev. Anticancer Ther. 2014; 14(1): 1-4.Saadatmand S., Rutgers E.J., Tollenaar R.A. et al. Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial. BMC Cancer. 2012; 12: 440.Venturini E., Losio C., Panizza P., Rodighiero M.G., Fedele I., Tacchini S. et al. Tailored breast cancer screening program with microdose mammography, US, and MR Imaging: shortterm results of a pilot study in 40-49-year-old women. Radiology. 2013; 268(2): 347-55.Mann R.M., Bult P., van Laarhoven H.W. et all. Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients. Eur. J. Radiol. 2013; 82(9): 1416-22.